Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy.
about
Extracellular MicroRNA in liquid biopsy: applicability in cancer diagnosis and preventionBeyond high-dose methotrexate and brain radiotherapy: novel targets and agents for primary CNS lymphomaThe vanishing role of whole brain radiotherapy for primary central nervous system lymphomaRituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcomeHigh-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study.A phase 1 dose escalation study of idarubicin combined with methotrexate, vindesine, and prednisolone for untreated elderly patients with primary central nervous system lymphoma. The GOELAMS LCP 99 trial.Efficacy of Procarbazine, Lomustine, and Vincristine Chemotherapy for Recurrent Primary Central Nervous System LymphomasBiology and treatment of primary central nervous system lymphoma.Treatment options for central nervous system lymphomas in immunocompetent patients.Primary CNS lymphoma in children and adolescents: a descriptive analysis from the International Primary CNS Lymphoma Collaborative Group (IPCG).Monotherapy with methotrexate for primary central nervous lymphoma has single agent activity in the absence of radiotherapy: a single institution cohort.Cognitive Sparing during the Administration of Whole Brain Radiotherapy and Prophylactic Cranial Irradiation: Current Concepts and Approaches.Low-dose whole brain radiotherapy with tumor bed boost after methotrexate-based chemotherapy for primary central nervous system lymphoma.Meningeal dissemination in primary CNS lymphoma: diagnosis, treatment, and survival in a large monocenter cohortHigh-dose methotrexate and rituximab with deferred radiotherapy for newly diagnosed primary B-cell CNS lymphomaEarly complete response during chemotherapy predicts favorable outcome in patients with primary CNS lymphoma.Pharmacotherapy for primary CNS lymphoma: progress beyond methotrexate?Isolated central nervous system relapse of systemic lymphoma (SCNSL): clinical features and outcome of a retrospective analysisR-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma.Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase II study by the Nordic Lymphoma GroupAggressive B-cell lymphomas: how many categories do we need?Leukoencephalopathy and disseminated necrotizing leukoencephalopathy following intrathecal methotrexate chemotherapy and radiation therapy for central nerve system lymphoma or leukemia.Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI.Immunochemotherapy for primary central nervous system lymphoma with rituximab, methotrexate, cytarabine and dexamethasone: Retrospective analysis of 18 casesImaging and therapy with rituximab anti-CD20 immunotherapy in an animal model of central nervous system lymphoma.Controversies in primary CNS lymphoma.Successful treatment of primary central nervous system lymphoma without irradiation in children: single center experience.Association of transcobalamin c. 776C>G with overall survival in patients with primary central nervous system lymphomaAn unusual instrumentation-related s1 radiculopathy in a patient treated for a primary vertebral (l3) lymphoma.International Central Nervous System and Ocular Lymphoma Workshop: recommendations for the futureCirculating U2 small nuclear RNA fragments as a novel diagnostic biomarker for primary central nervous system lymphoma.The methionine synthase polymorphism D919G alters susceptibility to primary central nervous system lymphoma.Cognitive functions in primary central nervous system lymphoma: literature review and assessment guidelines.High-dose methotrexate for elderly patients with primary CNS lymphoma.Blood-brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi-institutional experience.Association of genetic variants of methionine metabolism with methotrexate-induced CNS white matter changes in patients with primary CNS lymphoma.Recent advances in treatment of primary central nervous system lymphoma.Efficacy and MRI of rituximab and methotrexate treatment in a nude rat model of CNS lymphoma.Diagnosis and management of primary intraocular lymphoma: an updateTreatment approaches for primary CNS lymphomas.
P2860
Q26742027-38F0D3D8-B4EC-4BD5-8492-7335E11177E0Q27013785-1C80C6EE-F43B-4964-A2BB-2223EF388069Q27025006-9DB5F5EB-CDC5-4BAA-B41C-7887256A5BD1Q30457046-464D9D08-C30D-493A-9B84-FDD9BB19B668Q33381778-05F929D3-0347-4C2B-B82E-A5E6938E8420Q33416656-29C3D509-2544-4C4A-9E7E-363F1D5D3AACQ33427856-3D13EB7F-9E19-46D8-A9D8-7C37B4EBAE99Q33475480-9AE57991-4BC2-4CE5-A940-40C206AFFF5AQ33510785-A7F4F588-B8EE-4061-9A34-A1721DF18A28Q33759495-D9A3BBCC-1D05-4AB6-A77A-BBC7AACD0C1CQ33906988-23585062-8C0E-4A0A-9DC9-E5A062593D4BQ34021952-9FE33075-6C7E-4E17-BA12-6C734702D947Q34043390-66367010-B22F-4862-8B6F-B9EFB8DD313DQ34132849-E202A00B-65FB-4C58-B017-69CF4DDA0266Q34132988-3A4C945F-A38D-4DE4-8910-3A5AC96AB8EBQ34132992-2BE217B8-3F6A-42BB-8209-1660D9D023C2Q34190457-C0AE7A6C-E909-4867-A765-1B51822624E7Q35055829-6EBDE29E-2779-40E0-857B-2BAB9AB8F554Q35126247-79ED0F02-29E1-4F22-8690-F9332DAE3126Q35236072-FED8424B-C434-4B1A-8842-8D217D0CAAE5Q35527893-178EA7F8-DEFD-4D2C-8981-6E237E45B075Q35627088-A30034DF-8505-492F-8271-CF4400A17A21Q35783021-8F290615-9FC9-4372-8540-5E6D8BBE970EQ35802782-261AF0FC-43E2-49C1-B692-9E29DA29A1D0Q35914118-A388E5B7-4D12-4B2E-A521-99C23026467BQ36198587-36628D3A-EEB2-473B-B859-5C2217EC7EBDQ36381935-1B8DA8B0-16BB-430E-88B7-24613CC2E0CAQ36419151-EF6B7948-D3D5-462C-A7A4-5937DDCD75D6Q36436674-260E08E1-73B6-4DBD-91B3-5AAE2AFBFCB9Q36530118-6D02728B-297D-4A16-BE23-E437A2370BA8Q36618225-FDAF6C41-3CA8-4DDE-B3A1-EB2812CA0BE6Q36694144-FAD79AAE-E9A7-4362-8400-5656DD67340CQ36729827-6F4D04FB-446B-48CA-9197-E7B37B98241BQ37256189-D2DD86B6-EED8-44BE-B58F-1D903EF10833Q37280734-9594FC7C-2726-4A19-990E-3E9DDCFE9187Q37284222-206FD1A1-F618-4AFD-9F6A-99AF36CB9EF0Q37345440-4A8E6135-4687-4B03-9B37-B163B4308459Q37395346-DBEE54DC-7FE3-41FE-A9B5-5C826331DA19Q37577405-0DA2BB45-EB9E-4A8F-B1C9-EDBA8A46544AQ37739428-CAB82AC7-ED8F-4F53-B0F8-C2F3FA269E44
P2860
Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Primary central nervous system ...... py with deferred radiotherapy.
@en
Primary central nervous system ...... py with deferred radiotherapy.
@nl
type
label
Primary central nervous system ...... py with deferred radiotherapy.
@en
Primary central nervous system ...... py with deferred radiotherapy.
@nl
prefLabel
Primary central nervous system ...... py with deferred radiotherapy.
@en
Primary central nervous system ...... py with deferred radiotherapy.
@nl
P2093
P356
P1476
Primary central nervous system ...... py with deferred radiotherapy.
@en
P2093
Andreas Engert
Anton Zellner
Aslihan Atasoy
Axel Glasmacher
Carlo Schaller
Christoph Helmstaedter
Frank Kroschinsky
Gabriele Schackert
Gerlinde Egerer
Hendrik Pels
P304
P356
10.1200/JCO.2003.04.056
P407
P577
2003-11-03T00:00:00Z